This SuperSeries is composed of the SubSeries listed below.
Overall design: Refer to individual Series
| Accession | PRJNA864050; GEO: GSE210155 |
| Type | Umbrella project |
| Publications | Guo C et al., "SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity.", Nature, 2023 Aug;620(7972):200-208 |
| Submission | Registration date: 31-Jul-2022
Immunology, St Jude Children's Research Hospital |
| Relevance | Superseries |
Project Data:
| Resource Name | Number
of Links |
|---|
| Sequence data |
| SRA Experiments | 20 |
| Publications |
| PubMed | 1 |
| PMC | 1 |
| Other datasets |
| BioSample | 20 |
| GEO DataSets | 5 |
GEO Data Details| Parameter | Value |
|---|
| Data volume, Spots | 144230 |
| Data volume, Processed Mbytes | 4 |
| Data volume, Supplementary Mbytes | 853 |
| Parameter | Value |
|---|
| Data volume, Gbases | 722 |
| Data volume, Tbytes | 0.19 |
SLC38A2 and glutamine signaling in cDC1 dictate anti-tumor immunity encompasses the following 4 sub-projects:
| Project Type | Number of Projects |
| Epigenomics | 1 |
BioProject
accession | Organism | Title |
|---|
| PRJNA864057 | Mus musculus | SLC38A2 and glutamine signaling in cDC1 dictate anti-tumor immunity [ATAC-Seq] (Immunology, St Jude Children's...) |
|
| Transcriptome or Gene expression | 3 |
BioProject
accession | Organism | Title |
|---|
| PRJNA864054 | Mus musculus | SLC38A2 and glutamine signaling in cDC1 dictate anti-tumor immunity [scRNA-Seq 2] (Immunology, St Jude Children's...) | | PRJNA864056 | Mus musculus | SLC38A2 and glutamine signaling in cDC1 dictate anti-tumor immunity [scRNA-Seq 1] (Immunology, St Jude Children's...) | | PRJNA864048 | Mus musculus | SLC38A2 and glutamine signaling in cDC1 dictate anti-tumor immunity [array] (Immunology, St Jude Children's...) |
|